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Introduction: Although prone to a higher degree of ischemia reperfusion injury (IRI), the
use of extended criteria donor (ECD) organs has become reality in transplantation. We
therefore postulated that peri-operative perfusion of renal transplants with anti-human
T-lymphocyte globulin (ATLG) ameliorates IRI and results in improved graft function.
Methods: Weperformed a randomized, single-blinded, placebo-controlled trial involving
50 kidneys (KTx). Prior to implantation organs were perfused and incubated with ATLG
(AP) (n = 24 kidney). Control organs (CP) were perfused with saline only (n = 26 kidney).
Primary endpoint was defined as graft function reflected by serum creatinine at day 7
post transplantation (post-tx).
Results: AP-KTx recipients illustrated significantly better graft function at day 7 post-tx
as reflected by lower creatinine levels, whereas no treatment effect was observed
after 12 months surveillance. During the early hospitalization phase, 16 of the 26
CP-KTx patients required dialysis during the first 7 days post-tx, whereas only 10
of the 24 AP-KTx patients underwent dialysis. No treatment-specific differences were
detected for various lymphocytes subsets in the peripheral blood of patients. Additionally,
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mRNA analysis of 0-h biopsies post incubation with ATLG revealed no changes of
intragraft inflammatory expression patterns between AP and CP organs.
Conclusion: We here present the first clinical study on peri-operative organ
perfusion with ATLG illustrating improved graft function in the early period post kidney
transplantation.
Clinical Trial Registration: www.ClinicalTrials.gov, NCT03377283
Keywords: kidney transplantation, organ preservation, ATLG, ischemia reperfusion injury, RCT
INTRODUCTION
The growing demand for solid organs parallel with the decreasing
number of potential donors has led to the use of organs derived
from extended criteria donors (ECD) or organs retrieved after
circulatory death (DCD) (1). However, these organs show a
higher risk for unfavorable outcome as they are more susceptible
to ischemia reperfusion injury (IRI) (2, 3). In the need to improve
organ viability and function, most notably machine perfusion
has been proven to exert beneficial effects on organ preservation
in a number of experimental and clinical trials (4–7). However,
alternative approaches for the conditioning of donor organs are
missing so far.
IRI causes activation of the endothelium, resulting in
increased permeability and increased expression of adhesion
molecules, ultimately leading to increased attachment of
inflammatory leukocytes to the endothelium (8). Moreover,
reactive oxygen species, cytokines, chemokines, and adhesion
molecules are secreted and released, augmenting the
inflammatory immune response (9). Rabbit anti-thymocyte and
anti-lymphocyte globulins (rATG/ATLG) have been reported to
ameliorate IRI in numerous preclinical trials (10–12), primarily
mediated by binding to E-selectin and ICAM-1 expressed by
endothelial cells (13). Moreover, it was demonstrated that ATLG
binds to activated endothelial cell in vitro (14). These data
suggest that rATG/ATLG results in decreased inflammation
and overall protection of the perfused tissue. Whereas rATG is
the purified IgG fraction of sera from rabbits which have been
immunized with human thymocytes, ATLG is a based on a
preparation generated from rabbits immunized with the cultured
T-acute lymphoblastic leukemia cell line Jurkat (15). In solid
organ transplantation (SOT) rATG/ATLG is routinely applied in
the prevention and treatment of solid organ graft rejection (16),
mostly used as induction therapy (17, 18). Over the decades of
its application it has been demonstrated that this drug is safe and
highly potent in preserving allograft function following kidney
transplantation (KTx) (19, 20). This is supported by the fact that
the use of induction agents has increased over recent years as
reflected by the finding that in 2013 more than 89% of kidney
transplants in the United States were performed with induction
therapy (21). As we and others have already illustrated that rATG
induction therapy is also a safe and reasonable approach in liver
transplantation (22, 23), we explored the potential for perfusing
donor kidneys peri-operatively with ATLG in order to ameliorate




We performed a single-blinded, parallel randomized,
placebo-controlled trial at the Department of Visceral,
Transplant, and Thoracic Surgery of the Medical University of
Innsbruck, Austria. An interdisciplinary transplantation board
independently indicated the necessity for transplantation. Only
adult patients receiving a kidney transplant from deceased
donors were assessed for eligibility. Recipients diagnosed with
HCV/HIV, undergoing re-transplantation or under a public
guardian were not included.
Study Design
From 2012 to 2015 a total of 151 KTx recipients were assessed
for eligibility (Figure 1). In total, 50 kidney recipients were
eligible and enrolled in the study. Patients were randomly
assigned to the treatment groups in a 1:1 ratio using block
randomization and prepared randomization envelopes. For
perfusion of kidneys, 12.5mg of ATLG (Grafalon R©, Neovii
Biotech GmbH, Gräfelfing, Germany) was dissolved in 500ml
saline and administered via the renal artery. Organ perfusion
was performed after back table preparation prior to implantation.
After 5–10min of incubation, vessels were flushed with HTK
(Custodiol R©, Dr. Franz Köhler Chemie GmbH, Deutschland)
preservation solution to minimize systemic effects of “left-over”
ATLG. Biopsies were taken 1 h after reperfusion. In addition, pre-
(day−1) as well as post-transplantation (POD 0, 1, 3, 5, 7, 10,
15, month 3, and month 6), blood samples from recipients were
collected, immediately processed and stored in liquid nitrogen
until analysis. Immunosuppression was applied according to
the center’s protocol. Kidney recipients received basiliximab
induction therapy and maintenance immunosuppression with
tacrolimus, methylprednisolone, and mycophenolate mofetil
(MMF). Observation period of the study was defined until month
12 post-transplantation (last patient visit).
Endpoints
Primary endpoints of the study were determined as change in
graft function at day 7 from baseline defined by serum. Key
secondary endpoints were graft function and patient survival at
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FIGURE 1 | ATLG binding within the kidney. (A) ATLG binding to kidney structures was detected via binding of anti-rabbit polymer and visualization by Opal570 (red).
Autofluorescence of the tissue (green) was kept in order to visualize kidney tissue morphology. ATLG shows no binding to structures within the glomerulus. Original
magnification ×200, scale bar = 50µm. (B) ATLG binds to intravascular and extravasated leukocytes within the kidney. Leukocytes within vessels (filled arrowhead)
as well as leukocytes migrated into the kidney (blank arrowhead) show binding of ATLG (red). Autofluorescence of the tissue (green) was kept in order to distinguish
tissue structures and to visualize erythrocytes (arrow) and tubules (dotted arrow). Original magnification ×400, scale bar = 20µm. (C) Abundant leukocytes within a
peritubular capillary show ATLG binding (red). Autofluorescence (green) helps to distinguish erythrocytes and tubules. Original magnification ×400. (D) ATLG (red)
binds to the wall of peritubular capillaries (arrow) and leukocytes (arrowheads) within the kidney. Original magnification ×400, scale bar = 20µm. (E) No binding of
ATLG was detected in saline perfused control kidneys. Picture was taken with the same exposure time as used for treated kidney tissue sections. Original
magnification ×200, scale bar = 50µm. Representative pictures of n = 2 experiments with different organs are shown.
the end of the follow-up period (12 months). Graft function was
further assessed via estimated glomerular filtration rate (eGFR),
and serum urea for KTx. eGFR values were calculated by means
of the Modification of Diet in Renal Disease (MDRD4) formula
(24). Further secondary endpoints were defined for functional
parameters for time points other than primary outcome,
frequency of acute rejection, cytokine and lymphocyte expression
pattern. Clinical variables including recipient and donor age,
donor body mass index (BMI), recipient age, recipient BMI,
recipient sex, cold ischemia time (CIT), warm ischemia time
(WIT), presence of panel-reactive antibodies (PRA), hospital
stay, intensive care unit (ICU) stay, death/graft loss, number of
HLA mismatches, and development of delayed graft function
were considered for analysis.
Flow Cytometry
Mononuclear cells (MNC) from peripheral blood were isolated
by Ficoll (Sigma-Aldrich Corp., St. Louis, MO, USA) density
gradient centrifugation. For flow cytometry, 1 × 106 cells were
incubated for 15min at 4◦C with combinations of the antibodies
listed in Supplemental Table 1. Data were analyzed using FlowJo
software 9.3 (Tree Star Inc., Ashland, OR, USA), and the gating
strategy is illustrated in Supplemental Figure 1A. Absolute
leukocytes counts were evaluated at the Central Institute for
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Medical and Chemical Laboratory Diagnostics of the Innsbruck
Medical University in a daily routine (Supplemental Figure 1B).
Real-Time RT-PCR
Real-time RT-PCR was performed as recently described (25). In
brief, total RNA from snap-frozen biopsies was extracted using
the NucleoSpin RNA Kit (Macherey-Nagel, Düren, Germany)
according to the manufacturer’s instructions. Integrity of RNA
was checked using a NanoDropTM 2000c spectrophotometer.
Real-time reverse transcription polymerase chain reaction (RT-
PCR) for gene expression analysis was performed with the ABI
PRISM 7500 Sequence Detection System (Life Technologies,
Carlsbad, CA, USA). Primers were directly purchased as
Taqman R© gene expression assays (Life Technologies, Carlsbad,
CA, USA) (Supplemental Table 2). Specific gene expression was
normalized to the housekeeping gene hypoxanthine-guanine
phosphoribosyltransferase (HPRT) using the formula 2−1Ct.
Histology
Kidney tissue samples were fixed in 4% formalin overnight and
embedded in paraffin. Paraffin sections of 1–2µm thickness
were cut and dewaxed prior to heat-induced epitope retrieval.
Endogenous peroxidase was blocked and sections incubated
with an anti-rabbit polymer (EnVision; Agilent Santa Clara, CA,
USA) followed by Opal570 (PerkinElmer, Hamburg, Germany).
Sections were pressure cooked and nuclei stained with DAPI
(Sigma-Aldrich, Darmstadt, Germany). After coverslipping
with Fluoromount-G (Invitrogen GmbH, Karlsruhe, Germany)
sections were analyzed using a Zeiss AxioImager Z1 (Carl Zeiss
Microscopy GmbH, Jena, Germany). Controls were performed
by omitting the anti-rabbit polymer.
Statistics
Primary analysis was performed in the intention-to-treat (ITT)
population. Missing data for the primary analysis of longitudinal
clinical parameters (percentage of change from baseline prior
to transplantation) were not imputed since mixed models
were applied for comparison adjusted for baseline. Kaplan-
Meier plots were used to analyze overall survival, and a log-
rank test was applied to assess the statistical significance of
differences between survival curves. Sensitivity adjustments were
TABLE 1 | Donor and recipient characteristics KTX.
Variable Total (n = 50) ATG-perfused (n = 24) Control-perfused (n = 26) p-value#
Recipient age (yrs ± SD)* 54 ± 14 56 ± 13 53 ± 15 0.465
Recipient gender (females)*** 14/50 7/24 7/26 1.000
Recipient BMI (kg/m² ± SD)* 25 ± 5 25 ± 5 26 ± 5 0.571
Cold ischemic time (hours + IQR)** 13 (7) 11 (7) 14 (7) 0.222
Warm ischemic time (min + IQR)** 26 (10) 25 (10) 27 (8) 0.151
HLA Mismatch (number ± SD)* 3.4 ± 1 3.2 ± 2 3.6 ± 1 0.265
Panel reactive antibodies ≥20%*** 0/50 (0%) 0/24 (0%) 0/26 (0%) 1.000
DISEASE***
Polycystic kidney disease 11/50 (22%) 6/24 (25%) 5/26 (19%)
Diabetes Typ II 5/50 (10%) 3/24 (13%) 2/26 (8%)
IgA nephropathy 4/50 (8%) 1/24 (4%) 3/26 (12%)
Glomerulonephritis 4/50 (8%) 2/24 (8%) 2/26 (8%)
Hypertensive nephropathy 4/50 (8%) 2/24 (8%) 2/26 (8%)
Intestinal or pyelonephritis 3/50 (6%) 2/24 (8%) 1/26 (4%)
Alport syndrome 2/50 (4%) 0/24 (0%) 2/26 (8%)
Renal vascular disease 1/50 (2%) 0/24 (0%) 1/26 (4%)
Diabetes Typ I 1/50 (2%) 1/24 (4%) 0/26 (0%)
Membranoproliferative glomerulonephritis 1/50 (2%) 0/24 (0%) 1/26 (4%)
Chronic pyelonephritis 1/50 (2%) 0/24 (0%) 1/26 (4%)
Amyloidosis 1/50 (2%) 1/24 (4%) 0/26 (0%)
Focal segmental glomerulosclerosis 1/50 (2%) 1/24 (4%) 0/26 (0%)
Analgesic nephropathy 1/50 (2%) 0/24 (0%) 1/26 (4%)
Uncertain etiology 10/50 (20%) 5/24 (21%) 5/26 (19%)
DGF (dialysis after Tx) 26/50 10/24 16/26 0.257
Recipient ICU stay (days + IQR)** 1 (1) 1 (1) 1 (2) 0.855
Hospital stay (days + IQR)** 13 (14) 16 (18) 12 (11) 0.164
Donor age (yrs ± SD)* 51 ± 17 51 ± 17 51 ± 18 0.933
Donor BMI (kg/m² ± SD)* 26± 5 25 ± 4 26 ± 6 0.439
ECD Criteria*** 21/50 (42%) 8/24 (33%) 13/26 (50%) 0.233
*Mean + standard deviation; **median + interquartile range; ***count (percentage); #differences between ATLG and control.
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performed for age, recipient BMI, recipient gender. Due to
simple or co-primary defined endpoints multiplicity adjustment
was not required. Variables and endpoints were analyzed using
appropriate parametric or non-parametric statistical methods
based on their scale and distribution. All p-values from secondary
analyses were considered in a non-confirmatory, exploratory
way. Data were tested for normal distribution via visual analysis
using histograms. Flow cytometry and PCR data were analyzed
by applying a paired Mann-Whitney U test or Kruskal-Wallis
(with Dunn post-hoc) test. A p value below 0.05 was considered
statistically significant. Data analysis was performed using the
statistical software SPSS (IBM V22.0) and GraphPad Prism 5.
Study Approval
This study was conducted according to the Declaration of
Helsinki in accordance with good clinical practice guidelines,
and approved by an independent institutional ethics committee
of Innsbruck Medical University (ID: UN4640). All participants
provided written informed consent.
RESULTS
ATLG Binding Within the Kidney
For in situ detection of ATLG binding, we determined binding
of ATLG after perfusion of resected kidneys (n = 2) applying
the same set-up as for the renal transplants. As displayed in
Figures 1A–D, ATLG binds within a short incubation time of
5–10min. to intravascular and extravasated leukocytes within the
kidney as well as to the wall of peritubular capillaries. No binding
of ATLG was detected in saline perfused control kidneys.
Patients
In total, 24 subjects were randomly allocated to receive a kidney
transplant perfused with ATLG and 26 patients were randomly
allocated to receive a kidney transplant perfused with saline
only. Baseline characteristics were similar between both groups
(Table 1). In the ATLG group n = 8 patients and in the control
group n = 6 patients were lost to follow-up. After 12 months
n = 16 (ATLG) and n = 20 (control) patients completed the
observation period (Figure 2). No differences were detected for
donor and recipient age, gender or ischemic times. Whereas
only ten of the 24 patients in the ATLG group developed
delayed graft function (DGF), 16 of the 26 control patients
were diagnosed with DGF (41.6 vs. 61.5%; p = 0.257). Average
hospitalization did not significantly differ between patients in
the ATLG group as compared with controls (AP-KTx: 16 days
vs. CP-KTx: 12 days, p = 0.164; Table 1). Surgical, infectious
or other complications did not significantly differ in the two
study arms. The occurrence of adverse events is summarized in
Table 2.
FIGURE 2 | ATLG kidney perfusion consort diagram.
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Renal Function After Kidney
Transplantation
Pre-transplantation, no differences in creatinine output were
detected between the ATLG and the control group (AP-KTx:
7.4 ± 3.2 mg/dL vs. CP-KTx: 7.6 ± 2.7 mg/dL) (Figure 3),
and creatinine levels steadily decreased in the early post-
transplantation period until day 10. With respect to our defined
primary endpoint, ATLG recipients demonstrated significantly
better graft function regarding creatinine as compared with
controls at day 7 (AP-KTx: 2.7 mg/dL ± 1.9 mg/dL vs. CP-KTx:
4.0 mg/dL ± 2.9 mg/dL; p = 0.045) and even at day 5 (AP-KTx:
3.3 mg/dL ± 2.2 mg/dL vs. CP-KTx: 4.8 mg/dL ± 3.1 mg/dL,
p = 0.015). Similar observations were made for urea, illustrating
significantly lower values at days 5 and 7 for the ATLG group as
compared with the controls (day 5: AP-KTx: 119.8 mg/dL± 54.8
mg/dL vs. CP-KTx: 145.4 mg/dL ± 48.7 mg/dL, p = 0.038 and
day 7: AP-KTx: 108.3 mg/dL ± 53.7 mg/dL vs. CP-KTx: 134.8
mg/dL ± 53.6 mg/dL; p = 0.031). From day 15 until 3 months
post transplantation creatinine and urea showed a clear decline
and remained stable for the observation period of 12 months,
illustrating no further differences between ATLG and control
patients. Although the calculated estimated glomerular filtration
rate (eGFR) revealed better graft function for patients receiving
ATLG-perfused kidneys in the early transplantation phase, these
differences were not statistically relevant (Figure 3).
Peri-Operative Perfusion of the Kidney
With ATLG Does Not Result in
Inflammatory Changes
In order to evaluate potential effects on intragraft inflammatory
expression pattern, we analyzed renal biopsies retrieved 1 h
post-reperfusion of the two kidney cohorts. From the available
biopsy specimens we analyzed adhesion molecules including
intercellular adhesionmolecule 1 (ICAM-1), vascular cell adhesion
molecule 1 (VCAM-1) and E-Cadherin by gene expression
analysis, in order to study potential effects of ATLG perfusion.
However, no differences were detected between ATLG- and
control-perfused kidneys for these markers. Moreover, additional
candidate genes being indicative for kidney injury including
transforming growth factor beta (TGFß), the kidney injury
molecule 1 (KIM-1) or Lipocalin 2 (LCN2) further did not
show any significant differences between the investigated groups.
To examine whether genes responsible for cell migration are
affected by ATLG perfusion, we exemplarily investigated the CC-
chemokine ligand 21 (CCL21), which has been shown by us and
others to be upregulated during renal rejection (26, 27). Again,
no significant differences for CCL21 gene expression could be
observed (Figure 4).
Impact of Kidney Transplantation on
Peripheral Blood Lymphocytes
Post-transplantation
We further investigated various lymphocyte subsets in the
peripheral blood of kidney recipients. In general, no fundamental
differences between the intervention and the control group were
detected, but we observed clear transplant-related changes for








Ureter necrosis 3/50 (6%) 2/24 (8%) 1/26 (4%)
Vesicoureteral reflux 2/50 (4%) 0/24 (0%) 2/26 (8%)
Lymphocele 2/50 (4%) 0/24 (0%) 2/26 (8%)
Incisional hernia 2/50 (4%) 0/24 (0%) 2/26 (8%)
Bleeding 1/50 (2%) 1/24 (Tx loss) 0/26 (0%)
INFECTIONS***
Polyomavirus 4/50 (8%) 2/24 (8%) 2/26 (8%)
CMV reactivation or
infection
4/50 (8%) 2/24 (8%) 2/26 (8%)
Aspergillom 1/50 (2%) 0/24 (0%) 1/26 (4%)




2/50 (4%) 1/24 (4%) 1/26 (4%)
Primary non-function 1/50 (2%) 0/24 (0%) 1/26 (4%)
Death (unknown
reason)
1/50 (2%) 0/24 (0%) 1/26 (4%)
Prostate cancer 1/50 (2%) 1/24 (4%) 0/26 (0%)
Renal cell carcinoma
(remnant kidneys)
1/50 (2%) 0/24 (0%) 1/26 (4%)
***Count (percentage) some patients had >1 event.
various blood lymphocyte subsets. For instance, CD3+ T cell
frequencies declined during the early transplantation period
for both groups (until day 7 post-tx), finally resulting in a
significant increase by month 6 (AP-KTx: 32.5% ± 18.7% vs.
55.7% ± 18.4%, p = 0.0078; CP-KTx: 28.9 ± 14.4 vs. 53.2 ±
10.6, p = 0.0078; day 7 vs. month 6, respectively). Decreased
frequencies during the early post-transplant period appear to
be more evident for CD4+ T cells, although not statistically
significant (Figure 5). Interestingly, the most dramatic change
was observed for CD19+ B cells. Whereas B cells remained
unaffected in the ATLG group until day 7 post-transplantation,
their frequencies significantly increased until day 7 in the control
group (CP-KTx: 23.55% ± 12.8% vs. 42.1% ± 15.9%, pre Tx
vs. day 7; p = 0.042). However, compared with pre-transplant
levels and day 7 both kidney recipient groups exhibited a
significant decrease in CD19+ B cells at month 6 (AP-KTx:
36.1% ± 15.8% vs. 11.6% ± 5.8%, p = 0.001; CP-KTx: 43.1%
± 15.9% vs. 14.9% ± 7.5%, p = 0.001; day 7 vs. month 6,
respectively). No further significant changes were detected for
CD8+ T cells, double-negative (DN) CD4−CD8− T cells, or
CD56+CD3− NK cells (Figure 5). Focusing on T cell subsets,
ATLG resulted in induction of naïve CD4+ and naïve CD8+
T cells as well as in CD4+ and CD8+ central memory T
(TCM) cells in the early post-transplantation period, although
this observation was only significant for CD4+ TCM (AP-KTx:
7.3% ± 6.7% vs. 19.46% ± 16.4%, p = 0.006; pre Tx vs. day 7)
(Supplemental Figure 2).
Age-Related Effects of ATLG Perfusion
We recently addressed whether 0 h biopsies reveal markers for
cellular senescence, illustrating that the majority of candidate
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FIGURE 3 | Clinical parameters following KTX. The functional parameters creatinine and urea as well as the calculated eGFR illustrate a comparable course between
kidneys peri-operatively perfused with ATLG or saline eGFR until month 12 post-transplantation. However, ATLG recipients demonstrated significantly better graft
function regarding creatinine as compared with controls at days 5 and 7 (p = 0.015 and p = 0.045). ATLG: open boxes, control: filled boxes; data are presented as
mean values ± SEM; *p < 0.05.
genes were upregulated in donor organs aged >55 years (28). In
order to evaluate potential age-related effects of ATLG perfusion,
we chose an analogous cut-off to dichotomize donor groups in
ATLG≤55 years (APD young; n= 14, donor mean age 38.9) and
>55 years (APD old; n = 10, donor mean age 66.9) as well as
for the control group ≤55 years (CPD young; n = 12 mean age
35.6) and >55 years (CPD old; n = 14 mean age 64.2). Whereas
no differences were detectable between APD young and CPD
young organs, we observed significantly better graft function in
the APD old group as compared to the CPD old group. This
was reflected by creatinine and urea values at day 3 and day 5
post-transplantation (creatinine: p = 0.015 and p = 0.008; urea:
p = 0.013; p = 0.047, Figure 6). However, when comparing aged
vs. young donor organs within the groups, indeed the younger
organs display significantly better graft function than do the aged
organs within the ATLG and the control group. This observation
remained significant until the end of the observation period of 12
months (Figure 7).
Patient and Graft Survival Rates 1 Year
Post-transplantation
Although primary the endpoint displayed a significant difference
for functional short term outcome in the treatment group, no
differences in patient nor graft survival were observed at the
end of the observation period (patient survival: AP-KTx 100%
vs. CP-KTx 96%, p = 0.38; graft survival: AP-KTx 96% vs. CP-
KTx 92%, p = 0.60). Organ losses were due to bleeding (AP-
KTx group) and ureter necrosis and primary non-function (PNF)
(CP-KTx group). Death occurred in only one patient in the
control group for unknown reason. Kaplan-Meier plots for graft
survival demonstrate a similar trend (Figure 8).
DISCUSSION
The conditioning of ECD or DCD transplants in order to
optimize graft quality for better transplant outcome currently
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FIGURE 4 | mRNA analysis of candidate genes in kidney biopsies taken 1 h post-reperfusion. Data from available tissue specimens are shown. mRNA measurement
of selected candidate genes indicative for inflammation and adhesion did not reveal significant differences between ATLG-perfused kidneys and control kidneys.
ATLG: open boxes, control: filled boxes. Data are presented as mean ± SEM.
represents an urgent need in transplantation medicine. Whereas
the treatment of brain dead donors has been addressed in
only a small number of clinical trials (29–31), conditioning
of the organ by machine perfusion is currently considered in
a clearly larger number of clinical trials (4, 6, 32–34). These
studies mainly address the impact of hypothermic vs. cold storage
machine perfusion, whereas alternative approaches for organ
conditioning are tested solely in pre-clinical models (35–37) or
have been proven insufficient (38). In this context, targeting
IRI by applying various treatment schemes has been illustrated
in an extensive number of experimental trials (37, 39, 40).
For instance, ATLG was seen to be effective in preventing
IRI-associated renal function impairment, tissue damage and
tubular apoptosis when applying ATLG to the recipient (41).
Frontiers in Immunology | www.frontiersin.org 8 August 2018 | Volume 9 | Article 1911
Ritschl et al. Peri-Operative Kidney Perfusion With ATLG
FIGURE 5 | Frequencies of major lymphocyte subsets in the peripheral blood of kidney recipients. Recipients who received an ATLG-perfused organ and those who
received a saline-perfused organ illustrated similar frequencies of CD3+, CD4+, CD8+ T cells, CD4−CD8− T cells, CD19+ B cells, and CD56+CD3− NK cells.
Interestingly, whereas T cell frequencies appeared to decrease in the early postoperative days, there was a significant increase between day 7 post-transplantation
(POD 7) and month 6 (p = 0.0078, respectively). Moreover, both patient groups show a significant decrease in CD19+ B cells as compared with pre-transplant levels
and POD7 (p = 0.001, respectively). ATLG: open boxes, control: filled boxes; data are presented as mean ± SEM; *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001; *, difference
within AP; #, difference within CP; ## < 0.01, ### < 0.001.
This effect seemed to be related to the various antibodies
present in anti-thymocyte preparations affecting the binding and
surface expression of integrins (LFA-1, VLA-4) and adhesion
molecules involved in leukocyte/endothelial cell interaction (42).
Moreover, in a warm ischemia kidneymodel, application of rATG
resulted in reduced cell necrosis, cytoplasmic vacuolization,
cast formation, and tubular dilatation among ATG-treated rats
(43). As ATLG is an established immunosuppressant in SOT,
we aimed to address whether peri-operative perfusion with
ATLG results in amelioration of IRI by targeting adhesion-
and inflammation-inducedmolecules in a kidney transplantation
setting. To the best of our knowledge, this is the first clinical
trial that aims to optimize solid organs by perfusion with
antibodies.
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FIGURE 6 | Age-related effects of ATLG perfusion. Creatinine, urea levels and the calculated eGFR are displayed for donor organs grouped into either young (≤55
years, n = 14 for rATG perfused) or old organs (>55 years, n = 10, rATG perfused). Accordingly, donor organs were also grouped in young (≤55 years, n = 12) or old
(>55 years, n = 14). ATLG: open boxes, control: filled boxes; data are presented as mean values ± SEM; *p < 0.05, **p ≤ 0.01.
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FIGURE 7 | Age-related effects of young and old donor organs. Within the rATG and control group, graft outcome was separately analyzed for young (≤55 years) or
old (>55 years) donor age. ATLG: open boxes, control: filled boxes; data are presented as mean values ± SEM; *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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FIGURE 8 | Patient and graft survival at 1 year post-transplantation. Whereas
no differences in patient as well as graft survival were detected between
ATLG-perfused kidneys and control kidneys. (patient survival: AP-KTx 100%
vs. CP-KTx 96%, p = 0.38; graft survival: AP-KTx 96% vs. CP-KTx 92%,
p = 0.60).
In KTx, we detected improved renal function in the
early post-operative days as evidenced by lower creatinine
and urea levels at days 5 and 7 in the ATLG Group
(Figure 3) that meet the defined clinical primary endpoint.
The beneficial effect of ATLG was also demonstrated by the
lower incidence of DGF in the ATLG Group (Table 1). In an
explorative evaluation, it appeared that this effect was even
more pronounced in older organs (Figure 6). However, we were
not able to detect differences in graft function between ATLG
and control patients at the end of the 12-month observation
period.
Gene expression profiling of the organs did not reveal
differences in markers indicative for inflammation and
adhesion in kidney transplantation setting. In addition, no
differences were obtained for the main investigated lymphocyte
subsets with the exception of B cells, which demonstrated a
significant decrease at month 6 as compared to pre-transplant
frequencies in both kidney recipient groups. This shows that
this effect was unrelated to perfusion with ATLG (Figure 5)
confirming previous observations that B cells decline post
kidney transplantation, but illustrating a higher differentiation
status (44). The reason for this phenomenon remains to be
clarified.
Based on our observations, two pressing questions arise.
First, why ATLG-perfused kidneys show better graft function,
although we could not detect an influence of ATLG perfusion in
the allografted tissue at the molecular level. Second, why older
donor organs should benefit to a greater extent from ATLG
conditioning than younger organs although we were not able
to detect even subtle changes in the allograft. With respect to
the first question, we can only speculate that the time between
peri-operative perfusion of the organ and withdrawal of the renal
biopsy 1 h post-reperfusion was too short for detection of mRNA
changes. However, the benefit of ATLG in the KTx setting is
obvious and suggests that when binding to endothelial antigens
happened, adhesion, rolling and migration of leukocytes into
the tissue appeared to be ameliorated. As the limited amount
of material prevented us from evaluating the degree of tissue
infiltration, this assumption indeed remains speculative and
further studies are needed to address the potential effect of
ATLG perfusion in situ. Regarding the second question, the
general paradigm has been generated that aged organs display
greater immunogenicity than do younger organs by containing
larger numbers of dendritic cells that illustrate enhanced MHC II
expression, thus provoking a more intense alloimmune response
(45, 46). We therefore hypothesize that aged organs exhibit
stronger expression of endothelial antigens and therefore benefit
to a greater extent from ATLG perfusion than do younger
grafts.
We are aware of several limitations of our study. First, the
study’s relatively small sample size, which likely contributed to
underpowering to meet the defined study secondary endpoints.
Second, the duration of organ perfusion and incubation with
ATLG solution for 5min. might not be ideal for effective binding
of the polyclonal antibody to potential antigens. Upcoming
studies will clarify whether prolonged incubation with ATLG
or a combination with machine perfusion will contribute to a
more pronounced effect. However, perfusing solid organs with
ATLG might appear safer than the application of ATLG as
induction therapy shortly after surgery, as we demonstrated
stable lymphocyte populations post-transplantation. Recent data
from a large study cohort suggest that induction therapy
with rATG results in serum sickness disease, which is a
risk factor for graft loss in the long-term (47). Moreover,
rATG has been identified as being associated with a greater
risk for viral and bacterial infections post-transplantation
(17).
In conclusion, our data provide robust support for new
concepts in the peri-operative conditioning of solid organs. First,
the combination of machine perfusion and additional agents
including antibodies or alternative therapeutics (48, 49) may
provide a synergistic effect with regard to organ preservation and
reduction of IRI. Second, consideration of the influence of age is
strongly recommended for upcoming clinical trials.
Frontiers in Immunology | www.frontiersin.org 12 August 2018 | Volume 9 | Article 1911
Ritschl et al. Peri-Operative Kidney Perfusion With ATLG
AUTHOR CONTRIBUTIONS
PR, JP, and KK substantially contributed to the conception and
design of the study. PR, JG, LH, StE, SuE, AK, AS, FF, SW, CB,
AW, RO, BC, RÖ, SS, MB, CD, CM, TR, FA, and MM supported
acquisition of data, or analysis and interpretation of data. PR
and KK were responsible for writing the manuscript. All authors
revised the final version approved publication.
FUNDING
This work was supported by a grant from Deutsche
Forschungsgemeinschaft to JP and KK (DFG-PR578/2-3/4).
The authors of this manuscript received financial support from
Neovii Biotech GmbH for the study. The company had no role
in designing the study; in collection, analysis, or interpretation
of data; in writing the manuscript; or in the decision to submit
the paper for publication.
ACKNOWLEDGMENTS
We thank Anh-Vu Nguyen, Vanessa Mellitzer
and Nicole Bergmann for their excellent technical
support.
SUPPLEMENTARY MATERIAL




1. Locke JE, Segev DL, Warren DS, Dominici F, Simpkins CE, Montgomery
RA. Outcomes of kidneys from donors after cardiac death: implications
for allocation and preservation. Am J Transplant. (2007) 7:1797–807.
doi: 10.1111/j.1600-6143.2007.01852.x
2. Moers C, Kornmann NS, Leuvenink HG, Ploeg RJ. The influence of
deceased donor age and old-for-old allocation on kidney transplant outcome.
Transplantation (2009a) 88:542–52. doi: 10.1097/TP.0b013e3181b0fa8b
3. Brat A, Pol RA, Leuvenink HG. Novel preservation methods to increase the
quality of older kidneys. Curr Opin Organ Transplant. (2015) 20:438–43.
doi: 10.1097/MOT.0000000000000215
4. Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F,
Napieralski BP, et al. Machine perfusion or cold storage in deceased-
donor kidney transplantation. N Engl J Med. (2009b) 360:7–19.
doi: 10.1056/NEJMoa0802289
5. Compagnon P, Levesque E, Hentati H, Disabato M, Calderaro J, Feray
C, et al. An oxygenated and transportable machine perfusion system
fully rescues liver grafts exposed to lethal ischemic damage in a pig
model of DCD liver transplantation. Transplantation (2017) 101:e205–13.
doi: 10.1097/TP.0000000000001764
6. Gallinat A, Amrillaeva V, Hoyer DP, Kocabayoglu P, Benko T, Treckmann JW,
et al. Reconditioning by end-ischemic hypothermic in-house machine
perfusion: a promising strategy to improve outcome in expanded
criteria donors kidney transplantation. Clin Transplant. (2017) 31.
doi: 10.1111/ctr.12904
7. Tedesco-Silva HJ, Mello Offerni JC, Ayres Carneiro V, Ivani de Paula
M, Neto ED, Brambate Carvalhinho Lemos F, et al. Randomized trial of
machine perfusion versus cold storage in recipients of deceased donor kidney
transplants with high incidence of delayed graft function. Transplant Direct
(2017) 3:e155. doi: 10.1097/TXD.0000000000000672
8. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney
injury. J Clin Invest. (2011) 121:4210–21. doi: 10.1172/JCI45161
9. Linfert D, Chowdhry T, Rabb H. Lymphocytes and ischemia-reperfusion
injury. Transplant Rev. (2009) 23:1–10. doi: 10.1016/j.trre.2008.08.003
10. Beiras-Fernandez A, Chappell D, Hammer C, Thein E. Influence of
polyclonal anti-thymocyte globulins upon ischemia-reperfusion injury
in a non-human primate model. Transpl Immunol. (2006) 15:273–9.
doi: 10.1016/j.trim.2006.02.003
11. Cicora F, Roberti J, Lausada N, Gonzalez P, Guerrieri D, Stringa P, et al. Donor
preconditioning with rabbit anti-rat thymocyte immunoglobulin ameliorates
ischemia reperfusion injury in rat kidney transplantation. Transpl Immunol.
(2012) 27:1–7. doi: 10.1016/j.trim.2012.03.004
12. Watson MJ, Ke B, Shen XD, Gao F, Busuttil RW, Kupiec-Weglinski
JW, et al. Treatment with antithymocyte globulin ameliorates intestinal
ischemia and reperfusion injury in mice. Surgery (2012) 152:843–50.
doi: 10.1016/j.surg.2012.03.001
13. Michallet MC, Preville X, Flacher M, Fournel S, Genestier L,
Revillard JP. Functional antibodies to leukocyte adhesion molecules
in antithymocyte globulins. Transplantation (2003) 75:657–62.
doi: 10.1097/01.TP.0000053198.99206.E6
14. Kanzler I, Seitz-Merwald I, Schleger S, Kaczmarek I, Kur F, Beiras-Fernandez
A. In vitro effects of ATG-Fresenius on immune cell adhesion. Transplant
Proc. (2013) 45:1846–9. doi: 10.1016/j.transproceed.2013.01.079
15. Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit
antithymocyte globulin (thymoglobulin): 25 years and new frontiers in
solid organ transplantation and haematology. Drugs (2010) 70:691–732.
doi: 10.2165/11315940-000000000-00000
16. Webster AC, Wu S, Tallapragada K, Park MY, Chapman JR, Carr SJ.
Polyclonal and monoclonal antibodies for treating acute rejection episodes in
kidney transplant recipients. Cochrane Database Syst Rev. (2017) 7:CD004756.
doi: 10.1002/14651858.CD004756.pub4
17. Hill P, Cross NB, Barnett AN, Palmer SC, Webster AC. Polyclonal
and monoclonal antibodies for induction therapy in kidney
transplant recipients. Cochrane Database Syst Rev. (2017) 1:CD004759.
doi: 10.1002/14651858.CD004759.pub2
18. Zheng J, Song W. Alemtuzumab versus antithymocyte globulin induction
therapies in kidney transplantation patients: a systematic review and
meta-analysis of randomized controlled trials. Medicine (2017) 96:e7151.
doi: 10.1097/MD.0000000000007151
19. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ,
Hanto DW. Association of the type of induction immunosuppression
with posttransplant lymphoproliferative disorder, graft survival, and patient
survival after primary kidney transplantation. Transplantation (2003)
76:1289–93. doi: 10.1097/01.TP.0000100826.58738.2B
20. Lentine KL, Schnitzler MA, Xiao H, Brennan DC. Long-term safety and
efficacy of antithymocyte globulin induction: use of integrated national
registry data to achieve ten-year follow-up of 10-10 Study participants. Trials
(2015) 16:365. doi: 10.1186/s13063-015-0891-y
21. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Stewart DE,
et al. OPTN/SRTR 2013 annual data report: kidney. Am J Transplant. (2015)
15 (Suppl. 2):1–34. doi: 10.1111/ajt.13195
22. Stauch D, Yahyazadeh A, Bova R, Melloh GC, Fuldner A, Baron U, et al.
Induction of bona fide regulatory T cells after liver transplantation - the
potential influence of polyclonal antithymocyte globulin. Transpl Int. (2012)
25:302–13. doi: 10.1111/j.1432-2277.2011.01405.x
23. Halldorson JB, Bakthavatsalam R, Montenovo M, Dick A, Rayhill S, Perkins
J, et al. Differential rates of ischemic cholangiopathy and graft survival
associated with induction therapy in DCD liver transplantation. Am J
Transplant. (2015) 15:251–8. doi: 10.1111/ajt.12962
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate
method to estimate glomerular filtration rate from serum creatinine: a new
prediction equation. Modification of diet in renal disease study group. Ann
Intern Med. (1999) 130:461–70.
Frontiers in Immunology | www.frontiersin.org 13 August 2018 | Volume 9 | Article 1911
Ritschl et al. Peri-Operative Kidney Perfusion With ATLG
25. Ritschl PV, Ashraf MI, Oberhuber R, Mellitzer V, Fabritius C, Resch T, et al.
Donor brain death leads to differential immune activation in solid organs but
does not accelerate ischaemia-reperfusion injury. J Pathol. (2016) 239:84–96.
doi: 10.1002/path.4704
26. Kerjaschki D, Regele HM, Moosberger I, Nagy-Bojarski K, Watschinger B,
Soleiman A, et al. Lymphatic neoangiogenesis in human kidney transplants
is associated with immunologically active lymphocytic infiltrates. J Am Soc
Nephrol. (2004) 15:603–12. doi: 10.1097/01.ASN.0000113316.52371.2E
27. Kotsch K, Kunert K, Merk V, Reutzel-Selke A, Pascher A, Fritzsche
F, et al. Novel markers in zero-hour kidney biopsies indicate graft
quality and clinical outcome. Transplantation (2010) 90:958–65.
doi: 10.1097/TP.0b013e3181f546e8
28. Gunther J, Resch T, Hackl H, Sattler A, Ebner S, Ritschl PV, et al. Identification
of the activating cytotoxicity receptor NKG2D as a senescence marker in zero-
hour kidney biopsies is indicative for clinical outcome. Kidney Int. (2017)
91:1447–63. doi: 10.1016/j.kint.2016.12.018
29. Kotsch K, Ulrich F, Reutzel-Selke A, Pascher A, Faber W, Warnick P,
et al. Methylprednisolone therapy in deceased donors reduces inflammation
in the donor liver and improves outcome after liver transplantation: a
prospective randomized controlled trial. Ann Surg. (2008) 248:1042–50.
doi: 10.1097/SLA.0b013e318190e70c
30. Schnuelle P, Gottmann U, Hoeger S, Boesebeck D, Lauchart W, Weiss C, et al.
Effects of donor pretreatment with dopamine on graft function after kidney
transplantation: a randomized controlled trial. JAMA (2009) 302:1067–75.
doi: 10.1001/jama.2009.1310
31. Amatschek S,Wilflingseder J, PonesM, Kainz A, BodingbauerM,Muhlbacher
F, et al. The effect of steroid pretreatment of deceased organ donors on liver
allograft function: a blinded randomized placebo-controlled trial. J Hepatol.
(2012) 56:1305–9. doi: 10.1016/j.jhep.2012.01.020
32. Jochmans I, Moers C, Smits JM, Leuvenink HG, Treckmann J, Paul A, et al.
Machine perfusion versus cold storage for the preservation of kidneys donated
after cardiac death: a multicenter, randomized, controlled trial. Ann Surg.
(2010) 252:756–64. doi: 10.1097/SLA.0b013e3181ffc256
33. Watson CJ, Wells AC, Roberts RJ, Akoh JA, Friend PJ, Akyol M, et al. Cold
machine perfusion versus static cold storage of kidneys donated after cardiac
death: a UK multicenter randomized controlled trial. Am J Transplant. (2010)
10:1991–9. doi: 10.1111/j.1600-6143.2010.03165.x
34. O’Callaghan JM, Morgan RD, Knight SR, Morris PJ. Systematic review and
meta-analysis of hypothermic machine perfusion versus static cold storage
of kidney allografts on transplant outcomes. Br J Surg. (2013) 100:991–1001.
doi: 10.1002/bjs.9169
35. Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, et al.
Autologous mesenchymal stromal cells and kidney transplantation: a pilot
study of safety and clinical feasibility. Clin J Am Soc Nephrol. (2011) 6:412–22.
doi: 10.2215/CJN.04950610
36. Taba Taba Vakili S, Kailar R, Rahman K, Nezami BG, Mwangi SM, Anania FA,
et al. Glial cell line-derived neurotrophic factor-induced mice liver defatting:
a novel strategy to enable transplantation of steatotic livers. Liver Transpl.
(2016) 22:459–67. doi: 10.1002/lt.24385
37. Gregorini M, Corradetti V, Pattonieri EF, Rocca C, Milanesi S, Peloso A, et al.
Perfusion of isolated rat kidney with mesenchymal stromal cells/extracellular
vesicles prevents ischaemic injury. J Cell Mol Med. (2017) 21:3381–93.
doi: 10.1111/jcmm.13249
38. Krogstrup NV, Oltean M, Nieuwenhuijs-Moeke GJ, Dor FJ, Moldrup U,
Krag SP, et al. Remote ischemic conditioning on recipients of deceased
renal transplants does not improve early graft function: a multicenter
randomized, controlled clinical trial. Am J Transplant. (2017) 17:1042–9.
doi: 10.1111/ajt.14075
39. Kan C, Liu A, Fang H, Dirsch O, Dahmen U, Boettcher M. Induction of
autophagy reduces ischemia/reperfusion injury in steatotic rat livers. J Surg
Res. (2017) 216:207–18. doi: 10.1016/j.jss.2017.04.012
40. Manne N, Arvapalli R, Graffeo VA, Bandarupalli VVK, Shokuhfar T,
Patel S, et al. Prophylactic treatment with cerium oxide nanoparticles
attenuate hepatic ischemia reperfusion injury in sprague dawley
rats. Cell Physiol Biochem. (2017) 42:1837–46. doi: 10.1159/0004
79540
41. Aiello S, Cassis P, Mister M, Solini S, Rocchetta F, Abbate M, et al.
Rabbit anti-rat thymocyte immunoglobulin preserves renal function during
ischemia/reperfusion injury in rat kidney transplantation. Transpl Int. (2011)
24:829–38. doi: 10.1111/j.1432-2277.2011.01263.x
42. Mehrabi A, Mood Zh A, Sadeghi M, Schmied BM, Muller SA, Welsch T,
et al. Thymoglobulin and ischemia reperfusion injury in kidney and liver
transplantation. Nephrol Dial Transplant. (2007) 22 (Suppl. 8):viii54–60.
doi: 10.1093/ndt/gfm651
43. Gunay Y, Inal A, Yener N, Sinanoglu O, Selvi O, Bircan HY. A novel
mechanism of anti-T-lymphocyte globulin mediated by fractalkine in renal
ischemia-reperfusion injury in rats. Transplant Proc. (2013) 45:2461–8.
doi: 10.1016/j.transproceed.2013.02.118
44. van de Berg PJ, Hoevenaars EC, Yong SL, van Donselaar-van der Pant
KA, van Tellingen A, Florquin S, et al. Circulating lymphocyte subsets in
different clinical situations after renal transplantation. Immunology (2012)
136:198–207. doi: 10.1111/j.1365-2567.2012.03570.x
45. Heinbokel T, Hock K, Liu G, Edtinger K, Elkhal A, Tullius SG. Impact of
immunosenescence on transplant outcome. Transpl Int. (2013) 26:242–53.
doi: 10.1111/tri.12013
46. Oberhuber R, Heinbokel T, Cetina Biefer HR, Boenisch O, Hock K,
Bronson RT, et al. CD11c+ dendritic cells accelerate the rejection of
older cardiac transplants via interleukin-17A. Circulation (2015) 132:122–31.
doi: 10.1161/CIRCULATIONAHA.114.014917
47. Couvrat-Desvergnes G, Salama A, Le Berre L, Evanno G, Viklicky O,
Hruba P, et al. Rabbit antithymocyte globulin-induced serum sickness
disease and human kidney graft survival. J Clin Invest. (2015) 125:4655–65.
doi: 10.1172/JCI82267
48. Diuwe P, Domagala P, Durlik M, Trzebicki J, Chmura A, Kwiatkowski A. The
effect of the use of a TNF-alpha inhibitor in hypothermic machine perfusion
on kidney function after transplantation. Contemp Clin Trials (2017) 59:44–
50. doi: 10.1016/j.cct.2017.05.013
49. Sierra-Parraga JM, Eijken M, Hunter J, Moers C, Leuvenink H,
Moller B, et al. Mesenchymal stromal cells as anti-inflammatory and
regenerative mediators for donor kidneys during normothermic machine
perfusion. Stem Cells Dev. (2017) 26:1162–70. doi: 10.1089/scd.201
7.0030
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Ritschl, Günther, Hofhansel, Kühl, Sattler, Ernst, Friedersdorff,
Ebner, Weiss, Bösmüller, Weissenbacher, Oberhuber, Cardini, Öllinger, Schneeberger,
Biebl, Denecke, Margreiter, Resch, Aigner, Maglione, Pratschke and Kotsch. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Immunology | www.frontiersin.org 14 August 2018 | Volume 9 | Article 1911
